Business ❯Corporate Governance ❯Executive Accountability

Investor Relations

Shareholder Rights Financial Reporting Disclosure Obligations Class Action Lawsuits Market Impact Misleading Information Market Communications Public Companies Economic Loss Recovery Financial Disclosure Securities Violations Material Information Disclosure Legal Compliance

FDA Rejects Aldeyra's Reproxalap NDA for Dry Eye Disease Over Efficacy Issues

The decision marks the second rejection of the drug application, with Aldeyra planning a mid-2025 resubmission pending new trial results.

Warner Bros. Discovery Faces Investor Lawsuit Over Loss of NBA Media Rights